← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Thermo Fisher Scientific TMO $249B	2,077	+35	+2%	$173B
2	2 Danaher DHR $158B	1,821	+45	+3%	$151B
3	3 Novartis NVS $279B	1,120	-16	-1%	$19.8B
4	4 Illumina ILMN $41B	1,070	+24	+2%	$62.3B
5	5 Regeneron Pharmaceuticals REGN $80.1B	972	+48	+5%	$49.6B
6	6 Agilent Technologies A $49.1B	885	+12	+1%	$38.9B
7	7 Charles River Laboratories CRL $14.4B	639	+78	+14%	$17.6B
8	8 Revvity RVTY $17B	589	+6	+1%	$16.2B
9	9 ARK Genomic Revolution ETF ARKG $2.05B	514	+6	+1%	$2.37B
10	10 DELISTED CATALENT, INC. CTLT	509	+9	+2%	$18.2B
11	11 CRISPR Therapeutics CRSP $4.86B	499	+55	+12%	$6.57B
12	12 Guardant Health GH $21.9B	417	-2	-0.5%	$11.1B
13	13 Alnylam Pharmaceuticals ALNY $30B	401	+10	+3%	$19B
14	14 Azenta AZTA $1.63B	384	+47	+14%	$6.67B
15	NVTA 15 DELISTED Invitae Corporation NVTA	367	-6	-2%	$6.41B
16	16 10x Genomics TXG $9.52B	341	+17	+5%	$15.2B
17	17 Ionis Pharmaceuticals IONS $7.1B	338	-27	-7%	$4.96B
18	18 Intellia Therapeutics NTLA $1.6B	337	+76	+29%	$10B
19	19 Sarepta Therapeutics SRPT $1.78B	331	-36	-10%	$5.04B
20	20 Editas Medicine EDIT $349M	315	+1	+0.3%	$2.96B
21	21 Arrowhead Research ARWR $8.25B	314	+25	+9%	$5.55B
22	22 Bruker BRKR $8.47B	280	+34	+14%	$8.03B
23	23 Fate Therapeutics FATE $232M	272	+12	+5%	$8.2B
24	24 Pacific Biosciences PACB $619M	262	0	0%	$6.04B
25	25 Qiagen QGEN $9.41B	258	-17	-6%	$5.98B